2011
DOI: 10.4065/mcp.2011.0247
|View full text |Cite
|
Sign up to set email alerts
|

Current Concepts in Antifungal Pharmacology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
219
0
5

Year Published

2013
2013
2021
2021

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 310 publications
(225 citation statements)
references
References 105 publications
(100 reference statements)
1
219
0
5
Order By: Relevance
“…Neither echinocandins nor other triazoles are active against any of these species 5,7,8 . Cryptococcus neoformans is susceptible to polyenes, 5FC, all the triazoles, but not echinocandins 1,5,7,8,24,26 . The fungi that cause histoplasmosis, blastomycosis, and coccidioidomycosis exhibit in vitro susceptibility to polyenes and all triazoles 1,7,8 .…”
Section: Spectrum Of Activitymentioning
confidence: 98%
See 3 more Smart Citations
“…Neither echinocandins nor other triazoles are active against any of these species 5,7,8 . Cryptococcus neoformans is susceptible to polyenes, 5FC, all the triazoles, but not echinocandins 1,5,7,8,24,26 . The fungi that cause histoplasmosis, blastomycosis, and coccidioidomycosis exhibit in vitro susceptibility to polyenes and all triazoles 1,7,8 .…”
Section: Spectrum Of Activitymentioning
confidence: 98%
“…C. albicans and C. tropicalis are susceptible to all agents, but triazoles show minimal or variable activity against C. glabrata, and echinocandins exhibit the greatest activity 1,5,7,8 . Both polyenes and (particularly) echinocandins are active against C. krusei, while only voriconazole and to a lesser extent posaconazole exhibit reasonable activity 1,5,[7][8][9] . Polyenes and triazoles demonstrate good activity for C. parapsilosis, while echinocandins are less active against this pathogen.…”
Section: Spectrum Of Activitymentioning
confidence: 99%
See 2 more Smart Citations
“…7,10 Moreover, many newer antifungal agents have limitations in terms of their spectrum of activity, pharmacokinetics, and drug-drug interactions besides their uncommon toxicities related to their long-term use. 11 Therefore, looking for preexisting antifungals that have not been investigated yet for cutaneous candidiasis may arise as a possible surrogate to overcome the drawbacks of azoles and other new antifungal agents. Thus, the first scope of our study was to investigate an old synthetic Dovepress Dovepress 5532 elnaggar et al triazole vaginal antifungal known as terconazole (Tr) for the eradication of cutaneous candidiasis.…”
Section: Introductionmentioning
confidence: 99%